EUVIMEDEUVIMED entdecken
Crossref

Novel Rationally Designed Lipopeptides Derived from Bacitracin: Combating Multidrug Resistance and Evading Bacitracin Resistance via Potentiated Cell Wall and Membrane Inhibitions

Sijie Cheng, Jingwen Liao, Zhifu Chen, Fang Li, Yanping Zhu, Jinyong Zhang, Dongliang Guan iD

Journal of Medicinal Chemistry · 14.08.2025 · 68 (15) · 16410-16426

DOI: 10.1021/acs.jmedchem.5c01285 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 01.08.2025. Verfasst von Sijie Cheng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Molecular Pharmacology and Drug Evaluation, Ministry of Education, School of Pharmacy, Yantai University, Yantai, Shandong 264005, …. Hauptthemen laut MEDLINE: Bacitracin, Anti-Bacterial Agents, Drug Resistance, Multiple, Bacterial, Cell Wall. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Shandong Province Science Foundation for Youths.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The escalating threat posed by multidrug-resistant bacteria underscores the urgent need for novel antibiotics. Bacitracin, with its unique undecaprenyl pyrophosphate-targeting mechanism, serves as an ideal template for structural optimization. Herein, we developed a site-selective modification strategy targeting the 7-ornithine amino group, a critical yet underexplored residue in bacitracin. This approach revitalized bacitracin’s therapeutic potential against multidrug-resistant pathogens, achieving even up to 256-fold improved activity against methicillin-, vancomycin-, and daptomycin-resistant strains while systematically establishing previously unreported SAR at this locus. The lead compound, Bac-51, incorporating an optimized trifluoromethyl biphenyl moiety, demonstrated superior in vitro potency, favorable safety/pharmacokinetic profiles, and single-dose efficacy in a lethal MRSA sepsis murine model. Mechanistic studies revealed it has a dual mode of action: enhanced peptidoglycan biosynthesis inhibition and membrane-disrupting activity, which minimized resistance development and exhibited continuous efficacy against acquired bacitracin-resistant strains. Collectively, Bac-51 represents a next-generation bacitracin analog as a promising candidate for combating multidrug-resistant Gram-positive infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BacitracinAnti-Bacterial AgentsDrug Resistance, Multiple, BacterialCell WallLipopeptidesDrug DesignAnimalsMiceMicrobial Sensitivity TestsMethicillin-Resistant Staphylococcus aureusStructure-Activity RelationshipCell MembraneHumans

Substanzen

BacitracinAnti-Bacterial AgentsLipopeptides

Autor:innen und Institutionen

  • Key Laboratory of Molecular Pharmacology and Drug Evaluation, Ministry of Education, School of Pharmacy, Yantai University, Yantai, Shandong 264005, China.
  • Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, Shandong 264117, China.
  • National Engineering Research Center of Immunological Products, Department of Microbiology and Biochemical Pharmacy, College of Pharmacy, Army Medical University, Chongqing 400038, China.
  • Shanghai Institute of Materia Medica, Chinese Academy of Sciences, No. 555 Zuchongzhi Road, Pudong, Shanghai 201203, China.
  • University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, China.

ORCID-Profile: Dongliang Guan

Förderung

  • National Natural Science Foundation of China
  • Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery
  • Shandong Province Science Foundation for Youths

Zitieren

APA

Cheng, S., Liao, J., Chen, Z., Li, F., Zhu, Y., Zhang, J., & Guan, D. (2025). Novel Rationally Designed Lipopeptides Derived from Bacitracin: Combating Multidrug Resistance and Evading Bacitracin Resistance via Potentiated Cell Wall and Membrane Inhibitions. Journal of Medicinal Chemistry, 68(15), 16410-16426. https://doi.org/10.1021/acs.jmedchem.5c01285

Vancouver

Cheng S, Liao J, Chen Z, Li F, Zhu Y, Zhang J, et al. Novel Rationally Designed Lipopeptides Derived from Bacitracin: Combating Multidrug Resistance and Evading Bacitracin Resistance via Potentiated Cell Wall and Membrane Inhibitions. Journal of Medicinal Chemistry. 2025;68(15):16410-16426. doi:10.1021/acs.jmedchem.5c01285

BibTeX
@article{Cheng2025,
  author = {Cheng, Sijie and Liao, Jingwen and Chen, Zhifu and Li, Fang and Zhu, Yanping and Zhang, Jinyong and Guan, Dongliang},
  title = {Novel Rationally Designed Lipopeptides Derived from Bacitracin: Combating Multidrug Resistance and Evading Bacitracin Resistance via Potentiated Cell Wall and Membrane Inhibitions},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  volume = {68},
  number = {15},
  pages = {16410--16426},
  doi = {10.1021/acs.jmedchem.5c01285}
}
Kostenlos starten →